Regulus Therapeutics Inc.
RGLS
Rang in Aktien
#17278
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Aktienkurs
$8.16
Zuletzt synchronisiert: 2025-06-26
Marktkapitalisierung
$234.57M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-88.86%
Land
US
Handel Regulus Therapeutics Inc. (RGLS)
Kategorie
Healthcare
Kursverlauf für Regulus Therapeutics Inc. (RGLS)
Höchster Schlusskurs: $73.27 am 2024-11-01
Niedrigster Schlusskurs: $21.00 am 2010-04-01
Niedrigster Schlusskurs: $21.00 am 2010-04-01
Kursverlauf der Aktie von Regulus Therapeutics Inc. von 2010 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2024 | 113.53% |
| 2023 | 140.97% |
| 2022 | -61.38% |
| 2021 | -67.58% |
| 2020 | -13.91% |
| 2019 | 22.71% |
| 2018 | 12.94% |
| 2017 | 104.37% |
| 2016 | -25.20% |
| 2015 | -38.37% |
| 2014 | 34.13% |
| 2013 | 93.41% |
| 2012 | 67.05% |
| 2011 | 2.83% |
| 2010 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $516.67 | 21.21% |
US
|
|
| $248.20 | 802.87% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $880.72 | 5.51% |
NL
|
|
| $752.87 | 7.40% |
CH
|
